BRIEF — Sandoz Adds Emicizumab Biosimilar In Mabxience Deal
Sept 18 (Reuters) — SANDOZ GROUP AG: Sandoz Announces Collaboration With Mabxience To Expand Patient Access To Life-enhancing Biosimilar Medicines Agrees Emicizumab Biosimilar In $5.70 Billion Market; First Haemophilia Biosimilar In Pipeline Biosimilar Pipeline Expands To 40 Assets Following Agreement With Mabxience Source text:... Further company coverage: SDZ.S (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 587785269;)
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.